The ADAURA trial's MRD analysis reveals that a negative ctDNA test after surgery is not a reliable indicator of being cured. Patients still require adjuvant therapy, as recurrence remains a significant risk, especially within 12 months after stopping treatment.
In the LAURA trial, 56% of patients remained MRD-positive after definitive chemoradiation. This indicates that local therapy is often insufficient to eradicate the disease, suggesting early micrometastasis is common and providing a strong rationale for consolidation therapy.
The LAURA trial shows a favorable overall survival trend for osimertinib consolidation even though 80% of placebo patients received osimertinib upon progression. This high crossover rate makes the persistent trend highly significant, suggesting a strong benefit to earlier TKI administration.
Dr. Ramalingam describes a nuanced clinical approach based on early NEO ADORA data: using neoadjuvant chemo-osimertinib for N2 positive (Stage 3A) patients, but favoring upfront surgery followed by adjuvant therapy for Stage 2. This shows how specialists apply preliminary findings before they become universal standards.
While research pursues mechanism-based strategies (e.g., 4th-gen TKIs) for acquired resistance, recent practical breakthroughs are mechanism-agnostic, like ADCs or chemotherapy combinations. This highlights a pragmatic, broad-spectrum approach to treating progression after frontline osimertinib.
Data from the WUCONG-1B trial shows the TKI sunvosertinib's response rate is nearly halved in patients with prior exposure to the antibody amivantamab. This suggests a potential lack of efficacy after amivantamab and has major implications for treatment sequencing in this disease.